Disc Medicine CMO granted RSUs and options
Disc Medicine’s Chief Medical Officer William Jacob Savage reported new equity awards in the company’s stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Disc Medicine’s Chief Medical Officer William Jacob Savage reported new equity awards in the company’s stock. On February 10, 2026, he acquired 17,000 shares of Common Stock in the form of restricted stock units, bringing his direct Common Stock holdings to 95,845 shares.
He was also granted a stock option for 25,500 shares of Common Stock at an exercise price of $74.75 per share, all held directly. The option vests in 48 equal monthly installments beginning March 10, 2026, while the RSUs vest in four annual 25% installments starting February 15, 2027, in each case subject to his continued service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 25,500 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 17,000 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest annually in four 25% installments commencing on February 15, 2027, subject to the Reporting Person's continued service on each such vesting date.
- F2. The shares underlying this option shall vest in 48 equal monthly installments beginning on March 10, 2026, subject to the Reporting Person's continued service on each such vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.